[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Luo Yaping\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,67,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100603608","research-on-the-application-of-99mtc-tcr-fapi-spect-imaging-in-rheumatoid-arthritis-100603608",false,"NCT07138729","Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Age: 18-75 years old;\n2. Meet the classification criteria for rheumatoid arthritis of the American College of Rheumatology\u002FEuropean Union for Rheumatology in 2010;\n3. The highest disease activity in clinical practice (CDAI or SDAI score\n\nExclusion Criteria:\n\n1. Patients with other autoimmune diseases;\n2. Patients with concurrent tumors;\n3. Women who are pregnant or planning to become pregnant, women in the preconception period, pregnant and lactating women, and women with child-rearing plans during the study period; Subjects of childbearing age need to take effective contraceptive measures during the research process;\n4. Active infection\n5. Suffering from claustrophobia or other mental disorders, with poor compliance resulting in inability to cooperate with this researcher; (6) Situations where other researchers consider it inappropriate to participate in this clinical trial.","ALL","18 Years","75 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study proposes to evaluate 99mTc-CTR-FAPI SPECT imaging as a cost-effective, low-radiation, and widely accessible alternative to 68Ga-FAPI PET\u002FCT for assessing synovial lesions in RA patients, aiming to validate its diagnostic consistency with both PET\u002FCT and physical examinations while correlating imaging findings with clinical disease activity metrics to establish a practical tool for long-term RA monitoring.",[26],"Rheumatoid Arthritis (RA)",[28,29,30],"Rheumatoid arthritis","68Ga-FAPI PET \u002F CT","99mTc-CTR-FAPI SPECT","RECRUITING","2025-08-22",{"date":34,"type":35},"2025-08-24","ACTUAL",{"date":37,"type":35},"2025-05-10",{"date":39,"type":20},"2028-04-28",{"name":41,"class":42},"Luo Yaping","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100603607","research-on-the-application-of-68ga-dota-cck-fs-petct-in-mtc-100603607","NCT07138716","Research on the Application of 68Ga-DOTA-CCK-FS PET\u002FCT in MTC","Application Study of 68Ga-DOTA-CCK-FS PET\u002FCT in Medullary Thyroid Carcinoma (MTC) and Various Other Tumors With Positive Expression of Cholecystokinin-2 Receptor (CCK-2R)","Inclusion Criteria:\n\n1. Age not limited (male or female).\n2. Diagnosis:Confirmed or suspected medullary thyroid carcinoma (MTC) based on:\n\n   Fine-needle aspiration (FNA) cytology\u002Fhistopathology, or Elevated serum calcitonin\u002FCEA with thyroid nodule(s), or Clinical\u002Fhereditary suspicion (e.g., MEN2 syndrome), or Other histologically confirmed CCK-2R-positive tumors (e.g., neuroendocrine tumors, gastric\u002Fovarian cancers).\n3. Performance Status: Life expectancy ≥12 weeks.\n4. Contraception: Willingness to use effective birth control (if applicable).\n5. Consent: Signed informed consent and compliance with follow-up.\n\nExclusion Criteria:\n\n1. Severe hepatic\u002Frenal dysfunction (e.g., ALT\u002FAST \\>3×ULN, Cr \\>2.0 mg\u002FdL).\n2. Pregnancy\u002Flactation or planned pregnancy during the study.\n3. Inability to lie still for PET\u002FCT (e.g., severe claustrophobia).\n4. Concurrent conditions compromising study safety (investigator's judgment).\n\n\\*Note: CCK-2R positivity may be confirmed via prior immunohistochemistry (if available) or inferred from tumor type (e.g., MTC).\\*",true,{"count":53,"type":20},30,[23],"This study explores the clinical application of 68Ga-DOTA-CCK-FS PET\u002FCT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof. Luo Yaping (PUMCH Nuclear Medicine) and Prof. Liu Zhibo (Peking University, radiochemistry expert), the trial will enroll 30-40 patients to compare 68Ga-DOTA-CCK-FS imaging with standard PET\u002FCT (e.g., 18F-FDG or 68Ga-DOTATATE). The novel tracer shows higher tumor uptake and retention in preclinical studies, potentially improving diagnosis and treatment guidance for aggressive, CCK-2R-expressing cancers. The study leverages PUMCH's Class IV Radioactive Drug License for advanced radiopharmaceutical development. Risks are minimal (diagnostic radiation dose only), and participants receive free imaging assessments. Results aim to refine precision diagnostics for MTC and related tumors.",[57],"Medullary Thyroid Carcinoma",[59,60,61],"MTC","CCK-2R","PET\u002FCT",{"date":34,"type":35},{"date":37,"type":35},{"date":65,"type":20},"2028-12-01",{"name":41,"class":42},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100600943","a-study-on-the-effect-of-mrd-detected-by-fapi-pet--ct-on-the-recurrence-of-igg4-rd-100600943","NCT07104058","A Study on the Effect of MRD Detected by FAPI PET \u002F CT on the Recurrence of IgG4-RD","A Prospective Study on the Effect of Minimal Residual Disease Detected by Fibroblast Activation Protein PET \u002F CT on the Recurrence of IgG4-related Disease","Inclusion Criteria:\n\n1. age 18-75 years old ;\n2. Meet the 2019 ACR \u002F EURLAR IgG4-RD diagnostic criteria ;\n3. The disease was stable for more than 1 year, and the clinical evaluation of the disease was complete remission \\* ;\n4. Glucocorticoid dosage ≤ prednisone 7.5mg \u002F d × 6 months or more, or combined with an immunosuppressive therapy ( mycophenolate mofetil ) Ester ≤ 1.0g \u002F d, leflunomide ≤ 20mg \u002F d, methotrexate ≤ 15mg \u002F w, azathioprine ≤ 100mg \u002F d, iguratimod ≤ 25mg Bid )\n\nExclusion Criteria:\n\n( 1 ) Combined with other connective tissue disease patients ( 2 ) patients with tumor ; ( 3 ) women during pregnancy or planning pregnancy ; ( 4 ) active infection, including HIV, HCV, HBV, TB, etc. ; ( 5 ) Severe irreversible organ damage ; ( 6 ) In the active stage of the disease, the IgG4-RD reaction index score of the single affected organ was 2 points ; ( 7 ) stable condition less than 1 year ; ( 8 ) patients who relapsed within 1 year of previous hormone reduction and withdrawal ; ( 9 ) Combination of two or more immunosuppressive agents.",{"count":75,"type":20},46,[23],"This study intends to use the new technology of fibroblast activation protein PET \u002F CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET \u002F CT are related to the recurrence of IgG4-RD in patients with IgG4-RD who have been clinically evaluated for complete remission after treatment.",[79],"IgG4-Related Diseases",[79,81],"FAPI PET\u002FCT","2025-08-03",{"date":84,"type":35},"2025-08-05",{"date":37,"type":35},{"date":87,"type":20},"2027-12-01",{"name":41,"class":42},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":51,"sex":15,"minAge":16,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100590928","the-study-on-the-effectiveness-of-68gaga-hbed-cc-diasp-petct-in-calculating-gfr-and-predicting-residual-renal-function-after-partial-nephrectomy-100590928","NCT06973798","The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET\u002FCT in Calculating GFR and Predicting Residual Renal Function After Partial Nephrectomy","The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET\u002FCT in Calculating Glomerular Filtration Rate and Predicting Residual Renal Function After Partial Nephrectomy","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Patients with claustrophobia or fear of radiation;\n* Women who are planning to conceive, pregnant, or breastfeeding;\n* Patients unable to lie flat for 30 minutes;\n* Patients or family members who cannot understand the conditions and objectives of the study, or who refuse to participate.","88 Years",{"count":98,"type":20},40,[23],"In subjects with different levels of renal function and no history of renal tumors, GFR is measured using \\[68Ga\\]Ga-HBED-CC-DiAsp PET\u002FCT, the Gates method, and the 99mTc-DTPA dual plasma method. The consistency between the three methods is analyzed using intra-class correlation coefficient (ICC), concordance correlation coefficient (CCC), and Bland-Altman analysis.\n\nIn patients scheduled for partial nephrectomy due to renal tumors, GFR is measured using the three methods within 2 weeks before surgery and 4±1 weeks post-surgery. The percentage of postoperative residual renal function (postoperative GFR\u002Fpreoperative GFR × 100%, hereafter referred to as RRF%) is calculated for each method. By comparing and overlaying preoperative and postoperative PET\u002FCT images, the resected renal area can be delineated on the preoperative PET\u002FCT image. Based on the preoperative PET\u002FCT and the delineated surgical area, a predictive value for postoperative GFR is calculated to obtain the predicted RRF%. A consistency analysis is then performed between the predicted RRF% and the actual RRF% measured by the three methods, using ICC, CCC, and Bland-Altman analysis to evaluate the efficacy of \\[68Ga\\]Ga-HBED-CC-DiAsp PET\u002FCT in predicting residual renal function after partial nephrectomy.",[102,103,104],"Kidney Neoplasms \u002F Surgery","Glomerular Filtration Rate","Positron-Emission Tomography(PET)",[106,61,107,108],"[68Ga]Ga-HBED-CC-DiAsp","glomerular filtration rate","partial nephrectomy","NOT_YET_RECRUITING","2025-05-07",{"date":112,"type":35},"2025-05-15",{"date":114,"type":20},"2025-07-01",{"date":116,"type":20},"2025-11-10",{"name":41,"class":42},""]